CG Oncology, Inc. to Post FY2024 Earnings of ($2.00) Per Share, HC Wainwright Forecasts (NASDAQ:CGON)

CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Stock analysts at HC Wainwright raised their FY2024 EPS estimates for CG Oncology in a research report issued to clients and investors on Thursday, April 4th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($2.00) per share for the year, up from their prior forecast of ($2.01). HC Wainwright has a "Buy" rating and a $75.00 price target on the stock. The consensus estimate for CG Oncology's current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for CG Oncology's FY2025 earnings at ($2.37) EPS, FY2026 earnings at ($1.40) EPS and FY2027 earnings at ($0.85) EPS.

Other equities analysts also recently issued reports about the company. The Goldman Sachs Group initiated coverage on CG Oncology in a research report on Tuesday, February 20th. They set a "neutral" rating and a $42.00 price target on the stock. Morgan Stanley initiated coverage on CG Oncology in a research report on Tuesday, February 20th. They set an "overweight" rating and a $55.00 price target on the stock. Finally, Cantor Fitzgerald initiated coverage on CG Oncology in a research report on Tuesday, February 20th. They set an "overweight" rating and a $75.00 price target on the stock.

CG Oncology Trading Up 1.8 %

Shares of CGON stock traded up $0.69 during trading hours on Monday, reaching $39.15. 339,130 shares of the company's stock were exchanged, compared to its average volume of 691,581. The business's 50 day moving average price is $41.15. CG Oncology has a fifty-two week low of $28.55 and a fifty-two week high of $50.23.

Insider Activity at CG Oncology

In other news, Director Hong Fang Song bought 263,157 shares of the business's stock in a transaction that occurred on Monday, January 29th. The shares were purchased at an average cost of $19.00 per share, with a total value of $4,999,983.00. Following the transaction, the director now directly owns 613,928 shares in the company, valued at $11,664,632. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other CG Oncology news, Director Hong Fang Song purchased 263,157 shares of the stock in a transaction on Monday, January 29th. The shares were bought at an average cost of $19.00 per share, with a total value of $4,999,983.00. Following the completion of the acquisition, the director now owns 613,928 shares in the company, valued at $11,664,632. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Corleen M. Roche purchased 2,000 shares of the stock in a transaction on Monday, January 29th. The stock was acquired at an average cost of $19.00 per share, for a total transaction of $38,000.00. Following the completion of the acquisition, the chief financial officer now owns 2,000 shares of the company's stock, valued at approximately $38,000. The disclosure for this purchase can be found here. Insiders have bought a total of 666,472 shares of company stock valued at $12,662,968 in the last ninety days.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.